NYSE · CIK 0001860742
BLCO Bausch & Lomb Corp
Insider trading from SEC Form 4. Last filing Aug 7, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
16
with a Form 4 at this company
Signals
Open-market buys and sells at Bausch & Lomb Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Brent L Saunders CEO and Chairman of the Board buy | $248k 22,000 shares | +3% | - | |
| 15Weak | Andrew C. Von Eschenbach director buy | $20k 1,695 shares | +4% | - |
Transactions
The last 52 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 5, 2025 | Yehia Hashad EVP of R&D and CMO | AGrant or award Common Shares, No Par Value | +17,715 | $0.00 | $0 | 134,454 | Aug 7, 2025 |
| Aug 5, 2025 | Brent L Saunders CEO and Chairman of the Board | FTax withholding Common Shares, No Par Value | -4,231 | $14.44 | $61k | 736,925 | Aug 7, 2025 |
| Aug 5, 2025 | Frederick Munsch SVP, Controller and CAO | AGrant or award Common Shares, No Par Value | +7,529 | $0.00 | $0 | 77,733 | Aug 7, 2025 |
| Aug 5, 2025 | Luc Bonnefoy President, Surgical | AGrant or award Common Shares, No Par Value | +6,146 | $0.00 | $0 | 77,362 | Aug 7, 2025 |
| Aug 5, 2025 | Sam Eldessouky EVP and CFO | AGrant or award Common Shares, No Par Value | +42,517 | $0.00 | $0 | 320,816 | Aug 7, 2025 |
| Jul 25, 2025 | Sam Eldessouky EVP and CFO | FTax withholding Common Shares, No Par Value | -3,996 | $14.32 | $57k | 278,299 | Jul 28, 2025 |
| Jul 25, 2025 | Frederick Munsch SVP, Controller and CAO | FTax withholding Common Shares, No Par Value | -1,090 | $14.32 | $16k | 70,204 | Jul 28, 2025 |
| Jul 25, 2025 | Luc Bonnefoy President, Surgical | FTax withholding Common Shares, No Par Value | -2,167 | $14.32 | $31k | 71,216 | Jul 28, 2025 |
| Jul 25, 2025 | Yehia Hashad EVP of R&D and CMO | FTax withholding Common Shares, No Par Value | -2,841 | $14.32 | $41k | 116,739 | Jul 28, 2025 |
| Jul 21, 2025 | Brent L Saunders CEO and Chairman of the Board | AGrant or award Performance Stock Unitsderivative | +150,000 | $0.00 | $0 | 900,000 | Jul 23, 2025 |
| Jun 13, 2025 | Luc Bonnefoy President, Surgical | FTax withholding Common Shares, No Par Value | -968 | $12.33 | $12k | 73,383 | Jun 16, 2025 |
| May 27, 2025 | Sarah B Kavanagh director | AGrant or award Common Shares, No Par Value | +20,338 | $0.00 | $0 | 53,699 | May 28, 2025 |
| May 27, 2025 | Andrew C. Von Eschenbach director | AGrant or award Common Shares, No Par Value | +20,338 | $0.00 | $0 | 62,086 | May 28, 2025 |
| May 27, 2025 | Thomas W. Ross Sr. director | AGrant or award Common Shares, No Par Value | +20,338 | $0.00 | $0 | 60,391 | May 28, 2025 |
| May 27, 2025 | Russel C Robertson director | AGrant or award Common Shares, No Par Value | +20,338 | $0.00 | $0 | 64,914 | May 28, 2025 |
| May 27, 2025 | John Paulson director | AGrant or award Common Shares, No Par Value | +20,338 | $0.00 | $0 | 69,965 | May 28, 2025 |
| May 27, 2025 | Karen Ling director | AGrant or award Common Shares, No Par Value | +20,338 | $0.00 | $0 | 37,676 | May 28, 2025 |
| May 27, 2025 | Brett Icahn director | AGrant or award Common Shares, No Par Value | +20,338 | $0.00 | $0 | 61,147 | May 28, 2025 |
| May 27, 2025 | Gaoxiang Hu director | AGrant or award Common Shares, No Par Value | +20,338 | $0.00 | $0 | 61,147 | May 28, 2025 |
| May 27, 2025 | Nathalie D. Bernier director | AGrant or award Common Shares, No Par Value | +20,338 | $0.00 | $0 | 69,663 | May 28, 2025 |
| May 22, 2025 | Brent L Saunders CEO and Chairman of the Board | POpen-market purchase Common Shares, No Par Value | +22,000 | $11.28 | $248k | 719,156 | May 27, 2025 |
| May 22, 2025 | Brent L Saunders CEO and Chairman of the Board | AGrant or award Common Shares, No Par Value | +22,000 | $0.00 | $0 | 741,156 | May 27, 2025 |
| May 2, 2025 | Andrew C. Von Eschenbach director | POpen-market purchase Common Shares, No Par Value | +1,695 | $11.76 | $20k | 41,748 | May 6, 2025 |
| May 1, 2025 | John Paulson director | AGrant or award Common Shares, No Par Value | +1,887 | $11.59 | $22k | 49,627 | May 5, 2025 |
| May 1, 2025 | Russel C Robertson director | AGrant or award Common Shares, No Par Value | +2,210 | $11.59 | $26k | 44,576 | May 5, 2025 |
| Apr 24, 2025 | Andrew J. Stewart See remarks | FTax withholding Common Shares, No Par Value | -3,954 | $13.89 | $55k | 62,930 | Apr 25, 2025 |
| Apr 24, 2025 | A Robert D Bailey EVP & Chief Legal Officer | FTax withholding Common Shares, No Par Value | -9,781 | $13.89 | $136k | 170,576 | Apr 25, 2025 |
| Feb 28, 2025 | Luc Bonnefoy President,Surgical | FTax withholding Common Shares, No Par Value | -1,110 | $16.00 | $18k | 77,380 | Mar 3, 2025 |
| Feb 28, 2025 | Luc Bonnefoy President,Surgical | FTax withholding Common Shares, No Par Value | -3,029 | $16.00 | $48k | 74,351 | Mar 3, 2025 |
| Feb 26, 2025 | Luc Bonnefoy President,Surgical | AGrant or award Common Shares, No Par Value | +23,423 | $0.00 | $0 | 78,490 | Feb 28, 2025 |
| Feb 26, 2025 | Frederick Munsch SVP, Controller and CAO | AGrant or award Common Shares, No Par Value | +18,581 | $0.00 | $0 | 71,294 | Feb 28, 2025 |
| Feb 26, 2025 | Andrew J. Stewart See remarks | AGrant or award Common Shares, No Par Value | +23,423 | $0.00 | $0 | 66,884 | Feb 28, 2025 |
| Feb 26, 2025 | Yehia Hashad EVP of R&D and CMO | AGrant or award Common Shares, No Par Value | +25,225 | $0.00 | $0 | 119,580 | Feb 28, 2025 |
| Feb 26, 2025 | Brent L Saunders CEO and Chairman of the Board | AGrant or award Common Shares, No Par Value | +168,168 | $0.00 | $0 | 697,156 | Feb 28, 2025 |
| Feb 26, 2025 | A Robert D Bailey EVP & Chief Legal Officer | AGrant or award Common Shares, No Par Value | +40,540 | $0.00 | $0 | 180,357 | Feb 28, 2025 |
| Feb 26, 2025 | Sam Eldessouky EVP and CFO | AGrant or award Common Shares, No Par Value | +59,459 | $0.00 | $0 | 282,295 | Feb 28, 2025 |
| Feb 26, 2025 | Sam Eldessouky EVP and CFO | AGrant or award Non-Qualified Stock Options (right to purchase)derivative | +141,630 | $0.00 | $0 | 141,630 | Feb 28, 2025 |
| Feb 26, 2025 | Brent L Saunders CEO and Chairman of the Board | AGrant or award Non-Qualified Stock Options (right to purchase)derivative | +600,858 | $0.00 | $0 | 600,858 | Feb 28, 2025 |
| Feb 26, 2025 | Yehia Hashad EVP of R&D and CMO | AGrant or award Non-Qualified Stock Options (right to purchase)derivative | +60,085 | $0.00 | $0 | 60,085 | Feb 28, 2025 |
| Feb 26, 2025 | Andrew J. Stewart See remarks | AGrant or award Non-Qualified Stock Options (right to purchase)derivative | +55,793 | $0.00 | $0 | 55,793 | Feb 28, 2025 |
| Feb 26, 2025 | A Robert D Bailey EVP & Chief Legal Officer | AGrant or award Non-Qualified Stock Options (right to purchase)derivative | +96,566 | $15.86 | $1.5M | 96,566 | Feb 28, 2025 |
| Feb 26, 2025 | Luc Bonnefoy President,Surgical | AGrant or award Non-Qualified Stock Options (right to purchase)derivative | +55,793 | $0.00 | $0 | 55,793 | Feb 28, 2025 |
| Dec 23, 2024 | Andrew J. Stewart See remarks | FTax withholding Common Shares, No Par Value | -2,524 | $17.83 | $45k | 43,461 | Dec 26, 2024 |
| Dec 23, 2024 | Brent L Saunders CEO and Chairman of the Board | FTax withholding Common Shares, No Par Value | -73,782 | $17.83 | $1.3M | 553,637 | Dec 26, 2024 |
| Dec 23, 2024 | Frederick Munsch SVP, Controller and CAO | FTax withholding Common Shares, No Par Value | -908 | $17.83 | $16k | 54,905 | Dec 26, 2024 |
| Dec 23, 2024 | Yehia Hashad EVP of R&D and CMO | FTax withholding Common Shares, No Par Value | -2,324 | $17.83 | $41k | 97,106 | Dec 26, 2024 |
| Dec 23, 2024 | Sam Eldessouky EVP and CFO | FTax withholding Common Shares, No Par Value | -7,249 | $17.83 | $129k | 231,418 | Dec 26, 2024 |
| Dec 23, 2024 | A Robert D Bailey EVP & Chief Legal Officer | FTax withholding Common Shares, No Par Value | -4,402 | $17.83 | $78k | 139,817 | Dec 26, 2024 |
| Dec 23, 2024 | Yehia Hashad EVP of R&D and CMO | FTax withholding Common Shares, No Par Value | -2,751 | $17.83 | $49k | 94,355 | Dec 26, 2024 |
| Dec 23, 2024 | Sam Eldessouky EVP and CFO | FTax withholding Common Shares, No Par Value | -8,582 | $17.83 | $153k | 222,836 | Dec 26, 2024 |
| Dec 23, 2024 | Frederick Munsch SVP, Controller and CAO | FTax withholding Common Shares, No Par Value | -2,192 | $17.83 | $39k | 52,713 | Dec 26, 2024 |
| Dec 23, 2024 | Brent L Saunders CEO and Chairman of the Board | FTax withholding Common Shares, No Par Value | -24,649 | $17.83 | $439k | 528,988 | Dec 26, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- A Robert D BaileyEVP & Chief Legal Officer
- Nathalie D. Bernierdirector
- Luc BonnefoyPresident, Surgical
- Sam EldessoukyEVP and CFO
- Yehia HashadEVP of R&D and CMO
- Gaoxiang Hudirector
- Brett Icahndirector
- Sarah B Kavanaghdirector
- Karen Lingdirector
- Frederick MunschSVP, Controller and CAO
- John Paulsondirector, owner
- Russel C Robertsondirector
- Thomas W. Ross Sr.director
- Brent L SaundersCEO and Chairman of the Board
- Andrew J. StewartSee remarks
- Andrew C. Von Eschenbachdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.